Dx Deals: Labcorp Acquires Stake in European Testing Giant
$152.1 million SYNLAB deal is expected to create a new channel for Labcorp to market its sophisticated specialty assays
Deals-lir
Subscribe today for access to
Articles and Reports
Dx Deals: More than $62 Million Invested in Startup Labs in Recent Weeks
The rounds of funding to Clarapath, PreciseDx, and Precision Epigenomics come at a time when other M&A activity is seasonally slow
Dx Deals: Quest Makes Big North American Expansion with LifeLabs Acquisition
The roughly $1 billion deal will boost the company’s annual revenue by about 7 percent, and will give Quest a stronger presence in Canada
Thermo Fisher Acquisition of Qiagen Remains on Track
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Pandemic Infuses New Urgency Into Effort to Develop Genomics-Based Early PTSD Detection Diagnostics
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Danaher Closes $21.4 Billion GE Biopharma Acquisition
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
How Curative & KorvaLabs Created a Successful COVID-19 Testing Lab in Less than a Month
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Labs, Universities and Even Computer Companies Target Point-of-Care COVID-19 Test Development
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Diagnostic Deals: Urgent Need for Coronavirus Diagnostics Fuels Strategic Collaboration
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Diagnostic Deals: Urgent Need for Coronavirus Diagnostics Fuels Strategic Collaboration
...
This content is for Paid Members only.
Register
Register
Already a member? Log in here
Diagnostic Deals: Lab Corp & Quest to Continue Targeting Small and Independent Labs for Acquisition
PAMA price cuts were supposed to drive consolidation in the lab market. The expectation was that price pressures would make it impossible for smaller labs to remain independent, rendering them juicy targets for the likes of
Industry Buzz: The 10 Biggest DX Mergers of 2019
Conspicuous by its absence from the list is the proposed $1.2 billion Illumina takeover of Pacific Biosciences which suddenly seems to be in major trouble. Here are the 10-highest value M&A diagnostics deals that did come off in 2019.
Diagnostic Deals: Illumina/PacBio Merger Derails & Qiagen Takes Itself Out of Play
As 2019 came to a close, the biggest story in DX deal making was the pair of anticipated M&A deals that suddenly seem unlikely to happen. As a result, two major genetic testing companies will apparently continue as stand-alones in the coming year, one because it wants to and the other because it has to.